1. Therapeutic management of ALK+nonsmall cell lung cancer patients
   Boris Duchemann et al, 2015, European Respiratory Journal CrossRef
2. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer
   Helen Chow et al, 2015, Journal of Thoracic Oncology CrossRef
3. Assessment of ALK gene fusions in lung cancer using the differential expression and exon integrity methods
   QING HUANG et al, 2016, Oncology Letters CrossRef
4. Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer
   Raffaele Califano et al, 2017, Lung Cancer CrossRef
5. Evaluating the effectiveness of RNA in‐situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement
   Naoki Nakajima et al, 2017, Histopathology CrossRef
6. ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
   Paul Hofman, 2017, Cancers CrossRef
7. Real-World Data on Treatment Outcome of ALK-Positive Non-Small Cell Lung Cancer from an Indian Multicentric Cancer Registry
   Lalatendu Moharana et al, 2023, South Asian Journal of Cancer CrossRef
8. Targeting EP4 downstream c‐Jun through ERK1/2‐mediated reduction of DNMT1 reveals novel mechanism of solamargine‐inhibited growth of lung cancer cells
   Yuqing Chen et al, 2017, Journal of Cellular and Molecular Medicine CrossRef
9. Crizotinib
   Giuseppe Tridente, 2017, Adverse Events and Oncotargeted Kinase Inhibitors CrossRef
10. pH-sensitive polymeric nanocarriers for antitumor biotherapeutic molecules targeting delivery
    Jiayi Qin et al, 2021, Bio-Design and Manufacturing CrossRef